Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Sweden
/
Healthcare
Create a narrative
Healthcare Swedish Community
Our community narratives are driven by numbers and valuation.
Create a narrative
All companies
Popular
Undervalued
Overvalued
Healthcare Swedish Investing Ideas
Nanexa
DA
daemningen4500
Community Contributor
19,9% Novo Nordisk ownership on a small swedish biotech - could this be a significant technology?
Nanexa AB is a Swedish pharmaceutical company that specializes in drug delivery systems. Here's a brief overview of its corporate history, ownership, focus, and potential: Corporate History Nanexa was founded in 2007 and is headquartered in Uppsala, Sweden.
View narrative
SEK 1.30
FV
70.4% overvalued
intrinsic discount
28.21%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
26 days ago
author updated this narrative
EQL Pharma
MA
Mandelman
Community Contributor
EQL Pharma's management aiming for 30% Revenue Growth in 5 Years
2025 Q1 update Strong revenue growth yoy 45% exceding expectations. Strong EPS of 178%, however easy comps should be noted.
View narrative
SEK 86.37
FV
2.9% overvalued
intrinsic discount
30.00%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
17
users have followed this narrative
2 months ago
author updated this narrative
Dedicare
BO
Bonywall
Community Contributor
Staff Shortages and Demographic Shifts Could Drive Revenue Higher Despite Competition and Regulatory Challenges
Key Takeaways Dedicare holds a robust market position within a steadily expanding market. Continued revenue growth is supported by the persistent need for skilled health professionals.
View narrative
SEK 82.20
FV
46.5% undervalued
intrinsic discount
9.72%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
12 months ago
author updated this narrative
RaySearch Laboratories
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
RayStation And RayCare Upgrades Will Streamline Adaptive Treatment Planning
Key Takeaways Integration of AI and new treatment modules is anticipated to boost efficiency, driving demand and potential revenue growth for RaySearch. Expansion into new applications and increasing integration capabilities may significantly enhance market share and revenue prospects.
View narrative
SEK 335.00
FV
7.6% overvalued
intrinsic discount
13.87%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
2 days ago
author updated this narrative
Integrum
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
US Sales Focus And Axor II Will Boost Market Outlook
Key Takeaways Strategic focus on U.S. market growth and marketing optimization is expected to boost revenue and improve net margins. Near-term revenue prioritization and leadership changes aim to enhance market adoption and drive shareholder value.
View narrative
SEK 38.33
FV
48.3% undervalued
intrinsic discount
35.92%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
2 days ago
author updated this narrative
Senzime
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
US And European EMG Guidelines Will Spur TetraGraph Adoption
Key Takeaways Mandated EMG technology in Europe and the U.S. and new product launches set a strong growth trajectory, boosting sales and revenue. Expansion in the U.S. market and growth in Asia, coupled with strategic partnerships, enhance market penetration and diversify revenue streams.
View narrative
SEK 11.05
FV
47.1% undervalued
intrinsic discount
80.70%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
2 days ago
author updated this narrative
OssDsign
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Pure Play Orthobiologics Will Expand US Healthcare Access
Key Takeaways Strategic shift to orthobiologics boosts growth and operational efficiency, enhancing future revenue and sustaining high net margins. U.S. market expansion and distinctive product benefits position OssDsign for significant market share and increased adoption.
View narrative
SEK 14.60
FV
4.8% overvalued
intrinsic discount
28.16%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
2 days ago
author updated this narrative
Sedana Medical
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
US Trials And Supplier Acquisition Will Open Global Markets
Key Takeaways Successful U.S. trial results and pediatric approvals across multiple countries could significantly boost revenue and market protection, expanding sales demographics. Acquiring Innovatif Cekal is expected to enhance supply chain control, reduce costs, and improve profitability, with strong sales in Europe supporting consistent growth.
View narrative
SEK 20.90
FV
36.2% undervalued
intrinsic discount
25.18%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
2 days ago
author updated this narrative
Ambea
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Employee Satisfaction Efforts Will Reduce Turnover Costs And Improve Brand Trust
Key Takeaways Expansion of care services and strategic acquisitions drive revenue growth, enhance economies of scale, and positively impact net margins. Operational efficiencies in existing operations and strategic investments like share buybacks boost profitability, supporting margin stability and increasing investor interest.
View narrative
SEK 133.79
FV
11.8% undervalued
intrinsic discount
6.18%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
2 days ago
author updated this narrative
Value any company in seconds
Popular companies